Van Amerongen 2002.

Methods	6 week randomised double blind study
Participants	Diagnosis: Inpatients with DSM‐III major depression Male and Female. Threshold of baseline severity: HDRS‐17>=17, MADRS>=25, improvement during washout phase less than 25% of the initial score, MMSE>=20 Total number of all allocated participants: N=109 Age: mean 46.7y (range 23‐70y) for milnacipran, mean 45.9 y (range 20‐71y) for imipramine; range 18‐70y for total sample
Interventions	Milnacipran 100mg N=53 Imipramine 150mg N=56 Fixed dosing schedule.
Outcomes	Hamilton Depression Rating Scale‐21 item, MADRS, CGI‐3, 100mm VAS for subjective depression
Notes	Funding: by industry
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "randomised". Probably done.
Allocation concealment (selection bias)	Unclear risk	Insufficient information.
Blinding (performance bias and detection bias) All outcomes	Low risk	Quote: "double‐blind"
Incomplete outcome data (attrition bias) All outcomes	High risk	Missing primary outcome at early phase.
Selective reporting (reporting bias)	High risk	Missing standard deviations.
Other bias	Unclear risk	Insufficient information to assess whether an important risk of bias exists.